Diagnosis of early atherosclerotic lesions, and selected atherosclerotic risk factors, in patients with systemic lupus erythematosus

Polskie Archiwum Medycyny Wewnetrznej

Volumn 119, Issue 11, 2009, Pages 736-742

  Fischer, Katarzyna ^a   Brzosko, Marek ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Antiphospholipid syndrome; Atherosclerosis; Imaging study; Risk factors; Systemic lupus erythematosus

Indexed keywords

ANTIMALARIAL AGENT; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; ENDOTHELIAL CELL ANTIBODY; GLUCOCORTICOID; GLYCERYL TRINITRATE; HYDROXYCHLOROQUINE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PHOSPHOLIPID ANTIBODY;

ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; ARTERIAL WALL THICKNESS; ARTERY DISEASE; ATHEROSCLEROTIC PLAQUE; B SCAN; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHRONIC INFLAMMATION; COURSE EVALUATION; DIAGNOSTIC VALUE; DISEASE SEVERITY; DOPPLER FLOWMETRY; DRUG MEGADOSE; EARLY DIAGNOSIS; ELASTICITY; ENDOTHELIAL DYSFUNCTION; FUNCTIONAL ASSESSMENT; HUMAN; NON INVASIVE PROCEDURE; PROVOCATION TEST; PULSE WAVE; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTOLIC BLOOD PRESSURE; TONOMETRY; VASCULAR RESISTANCE; VASODILATATION;

EID: 72149106149     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.827     Document Type: Review

References (78)

1. Bulkley BH, Roberts WC. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients. Am J Med. 1975; 58: 243-264.
2. Urowitz MB, Bookman AA, Koehler BE, et al. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 1976; 60: 221-225.
3. Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell. Science. 1973; 180: 1332-1339.
4. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993; 362: 801-809.
5. George J, Afek A, Gilburd B, et al. Autoimmunity in atherosclerosis: lessons from experimental models. Lupus. 2000; 9: 223-227. (Pubitemid 30199267)
6. Bruce IN. "Not only... but also": factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology. 2005; 44: 1492-1502.
7. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in woman with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol. 1997; 145: 408-415. (Pubitemid 27084212)
8. Urowitz MB, Gladman DD. Accelerated atheroma in lupus - background. Lupus. 2000; 9: 161-165.
9. Pearson JD. Normal endothelial cell function. Lupus. 2000; 9: 183-188.
10. Bijl M. Endothelial activation, endothelial dysfunction and premature atherosclerosis in systemic autoimmune diseases. Neth J Med. 2003; 61: 273-277. (Pubitemid 39089423)
11. Krishnaswamy G, Kelley J, Yerra L, et al. Human endothelium as a source of multifunctional cytokines: molecular regulation and possible role in human disease. J Interferon Cytokine Res. 1999; 19: 91-104. (Pubitemid 29109625)
12. Sorensen KE, Celermajer DS, Spiegelhalter DJ, et al. Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br Heart J. 1995; 74: 247-253.
13. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002; 39: 257-265.
14. Kiss E, Soltesz P, Der H, et al. Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus patients. J Autoimmun. 2006; 27: 211-217. (Pubitemid 46206103)
15. Wright SA, O'Prey FM, Rea DJ, et al. Microcirculatory hemodynamics and endothelial dysfunction in systemic lupus erythematosus. Arterioscler Thromb Vasc Biol. 2006; 26: 2281-2287. (Pubitemid 44465723)
16. El-Magadmi M, Bodill H, Ahmad Y, et al. Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation. 2004; 110: 399-404. (Pubitemid 38993848)
17. Hirata K, Kadirvelu A, Kinjo M, et al. Altered coronary vasomotor function in young patients with systemic lupus erythematosus. Arthritis Rheum. 2007; 56: 1904-1909.
18. Tanaka H, DeSouza CA, Seals DR. Absence of age-related increase in central arterial stiffness in physically active woman. Arterioscler Thromb Vase Biol. 1998; 18: 127-132. (Pubitemid 28047609)
19. Bjarnegård N, Bengtsson C, Brodszki J, et al. Increased aortic pulse wave velocity in middle aged women with systemic lupus erythematosus. Lupus. 2006; 15: 644-650. (Pubitemid 44682825)
20. Setzer F, Sutton-Tyrrell K, Fitzgerald S, et al. Vascular stiffness in women with systemic lupus erythematosus. Hypertension. 2001; 37: 1075-1082. (Pubitemid 32304007)
21. Roman MJ, Devereux RB, Schwartz MD, et al. Arterial stiffness in chronic inflammatory diseases. Hypertension. 2005; 46: 194-199. (Pubitemid 40946513)
22. Yambe T, Yoshizawa M, Saijo Y, et al. Brachio-ankle pulse wave velocity and cardio-ankle vascular index (CAVI). Biomed Pharmacother. 2004; 58 Suppl 1:S95-98.
23. Sato H, Miida T, Wada Y, et al. Atherosclerosis is accelerated in patients with long-term well-controlled systemic lupus erythematosus (SLE). Clin Chim Acta. 2007; 385: 35-42. (Pubitemid 47376930)
24. Izuhara M, Shioji K, Kadota S, et al. Relationship of cardio-ankle vascular index (CAVI) to carotid and coronary arteriosclerosis. Circ J. 2008; 72: 1762-1767.
25. Arbeille P, Berson M, Achaibou F, et al. Vascular resistance quantification in high flow resistance areas using the Doppler method. Ultrasound Med Biol. 1995; 21: 321-328.
26. Arbeille P, Berson M, Blondeau B, et al. (Quantification and monitoring of vascular resistance in the lower limbs by the Doppler method (animal model)). Arch Mal Coeur Vaiss. 1995; 88: 1029-1034. French.
27. Walecka A, Sawicki M, Brzosko M, et al. Value of high resistance index - HRI calculated from Doppler spectrum of popliteal arteries in patients with systemic lupus erythematosus (SLE). Med Sci Monit 2004; 10 Suppl 3: 58-62.
28. European guidelines regarding the prevention of circulatory system disease in clinical practice. The third recommendation of the joint committee of experts of the European Society, and other Scientific Societies charged with prevention of circulatory system diseases in clinical practice. Kardiol Pol. 2004; 61 Suppl 1: 1-92.
29. Theodoridou A, Bento L, D'Cruz DP, et al. Prevalence and associations of an abnormal ankle-brachial index in systemic lupus erythematosus: a pilot study. Ann Rheum Dis. 2003; 62: 1199-1203. (Pubitemid 37500627)
30. Barón MA, Khamashta MA, Hughes GR, D'Cruz DP. Prevalence of an abnormal ankle-brachial index in patients with primary antiphospholipid syndrome: preliminary data. Ann Rheum Dis. 2005; 64: 144-146.
31. Christodoulou C, Zain M, Bertolaccini ML, et al. Prevalence of an abnormal ankle-brachial index in patients with antiphospholipid syndrome with pregnancy loss but without thrombosis: a controlled study. Ann Rheum Dis. 2006; 65: 683-684.
32. Chambless LE, Zhong MM, Arnett D, et al. Variability in B-mode ultrasound measurements in the atherosclerosis risk in communities (ARIC) study. Ultrasound Med Biol. 1996; 22: 545-554. (Pubitemid 26230582)
33. Denarié N, Gariepy J, Chironi G, et al. Distribution of urtrasonographically-assessed dimensions of common carotid arteries in healthy adults of both sexes. Atherosclerosis. 2000; 148: 297-302. (Pubitemid 30064460)
34. Sun Y, Lin CH, Lu CJ, et al. Carotid atherosclerosis, intima media thickness and risk factors - an analysis of 1781 asymptomatic subjects in Taiwan. Atherosclerosis. 2002; 164: 89-94. (Pubitemid 34765641)
35. Homma S, Hirose N, Ishida H, et al. Carotid plaque and intima-media thickness assessed by B-mode ultrasonography in subjects ranging from young adults to centenarians. Stroke. 2001; 32: 830-835. (Pubitemid 32285143)
36. Ebrahim S, Papacosta O, Whincup P, et al. Carotid plaque, intima media thickness, cardiovascular risk factors, and prevalent cardiovascular disease in men and women. Stroke. 1999; 30: 841-850. (Pubitemid 29156378)
37. Takashi W, Tsutomu F, Kentaro F. Ultrasonic correlates of common carotid atherosclerosis in patients with coronary artery disease. Angiology. 2002; 53: 177-183. (Pubitemid 34263312)
38. O'Leary DH, Polak JF, Kronmai RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med. 1999; 340: 14-22. (Pubitemid 29024679)
39. Kaźmierski R, Kozubski W, Watala C. [Intima-media thickness of the common carotid arteries evaluated by ultrasound, as risk factors for cerebral ischemic stroke]. Neurol Neurochir Pol. 2000; 34: 243-253. Polish.
40. Chambless LE, Folsom AR, Clegg LX, et al. Carotid wall thickness is predictive of incident clinical stroke. The Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol. 2000; 151: 478-487.
41. Touboul PJ, Labreuche J, Vicaut E, et al. Carotid intima-media thickness, plaques, and Framingham risk score es independent determinants of stroke risk. Stroke. 2005; 36: 1741-1745. (Pubitemid 41098773)
42. Fischer K. Risk factors of thickened intima-media and atherosclerotic plaque development in carotid arteries in patients with systemic lupus erythematosus]. Ann Acad Med Stetin. 2008; 54: 22-32. Polish.
43. Doria A, Shoenfeld Y, Wu R, et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis. 2003; 62: 1071-1077. (Pubitemid 37323571)
44. Svenungsson E, Jensen-Urstad K, Heimbürger M, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation. 2001; 104: 1887-1893. (Pubitemid 32983229)
45. 2-glycoprotein I complexed with an oxidized lipoprotein relate to intima thickening of carotid arteries in primary antiphospholipid syndrome. Clin Develop Immunol. 2006; 13: 1-9.
46. Park YB, Ahn CW, Choi HK, et al. Atherosclerosis in rheumatoid arthtritis. Morphologic evidence obtained by carotid ultrasound. Arthritis Rheum. 2002; 46: 1714-1719.
47. Kumeda Y, Inaba M, Goto H, et al. Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum. 2002; 46: 1489-1497. (Pubitemid 34620194)
48. Swets BP, Brouwer DA, Tervaert JW. Patients with systemic vasculitis have increased levels of autoantibody against oxidized LDL. Clin Exp Immunol. 2001, 124: 163-167.
49. Ames PRJ, Margarita A, Sokoll KB, et al. Premature atherosclerosis in primary antiphospholipid syndrome: preliminary data. Ann Rheum Dis. 2005; 64: 315-317. (Pubitemid 40193636)
50. Boussel L, Serusclat A, Skilton MR, et al. The reliability of high resolution MRI in the measurement of early stage carotid wall thickening. J Cardiovasc Magn Reson. 2007; 9: 771-776. (Pubitemid 47463909)
51. Štalc M, Poredoš P, Peternel P, et al. Endothelial function is impaired in patients with primary antiphospholipid syndrome. Thromb Res. 2006; 118: 455-461. (Pubitemid 44308637)
52. Jimenez S, Garcia-Criado MA, Tássies D, et al. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology. 2005; 44: 756-761. (Pubitemid 41487204)
53. Vlachoyiannopoulos PG, Samarkos M. Peripheral vascular disease in antiphospholipid syndrome. Thromb Res. 2004; 114: 509-519. (Pubitemid 39422585)
54. Ostanek L, Plonska E, Peregud-Pogorzelska M, et al. [Cardiovascular abnormalities in systemic lupus erythematosus patients in echocardiographic assessment]. Pol Merkur Lekarski. 2006; 117: 305-308. Polish.
55. Ostanek L, Brzosko M, Fischer K, et al. [Antiphospholipid syndrome and antiphospholipid antibodies, as risk factors for coronary artery disease and myocardial infarction in patients with systemic lupus erythematosus]. Pol Arch Med Wewn. 2006; 5: 407-413. Polish.
56. Fischer K, Brzosko M, Walecka A, et al. [Significance of antiphospholipid syndrome and antiphospholipid antibodies in patients with systemic lupus erythematosus in estimation of risk of subclinical atherosclerosis development]. Pol Arch Med Wewn. 2007; 117 (Suppl 1): 13-17. Polish.
57. Glueck CJ, Lang JE, Tracy T, et al. Evidence that anticardiolipin antibodies are independent risk factors for atherosclerotic vascular disease. Am J Cardiol. 1999; 83: 1490-1494. (Pubitemid 29228349)
58. 2-glycoprotein I in the antiphospholipid antibody binding to endothelial cells. Lupus. 1995; 4: 179-186.
59. Bergmark C, Wu R, de Faire U, et al. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler Thromb Vasc Biol. 1995; 15: 441-445.
60. Faviou E, Vourli G, Nounopoulos C, et al. Circulating oxidized low density lipoprotein, autoantibodies against them and homocysteine serum levels in diagnosis and estimation of severity of coronary artery disease. Free Radic Res. 2005; 39: 419-429. (Pubitemid 40613721)
61. Fukumoto M, Shoji T, Emoto M, et al. Antibodies against oxidized LDL and carotid artery intima-media thickness in a healthy population. Arterioscler Thromb Vasc Biol. 2000; 20: 703-707. (Pubitemid 30151684)
62. Kabakov AE, Tertov W, Saenko VA, et al. The atherogenic effect of lupus sera: systemic lupus erythematosus-derived immune complexes stimulate the accumulation of cholesterol in cultured smooth muscle cells from human aorta. Clin Immunol Immunopathol. 1992; 62: 214-220.
63. Grainger DJ, Bethell HW. High titers of serum antinuclear antibodies, mostly directed against nucleolar antigens, are associated with the presence of coronary atherosclerosis. Ann Rheum Dis. 2002; 61: 110-114.
64. Pradhan VD, Badakere SS, Bichile LS, et al. Anti-neutrophil cytoplasmic antibodies (ANCA) in systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies. J Assoc Physicians India. 2004; 52: 533-537.
65. Van Haelst PL, Asselbergs FW, van Doormaal JJ, et al. Antineutrophil cytoplasmatic antibodies in patients with premature atherosclerosis: prevalence and association with risk factors. J Int Med. 2002; 251: 29-34.
66. Van Haelst PL, Muller Kobold AC, van Doormaal JJ, et al. AECA and ANCA in patients with premature atherosclerosis. Intern Rev Immunol. 2002; 21: 19-26.
67. Ewert BH, Jennette JC, Falk RJ. Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. Kidney Int. 1992; 41: 375-383.
68. Kubes P, Smith R, Grisham MD, et al. Neutrophil-mediated proteolysis. Differential roles for cathepsin G and elastase. Inflammation. 1993; 17: 321-332.
69. Selak MA, Chignard M, Smith JB. Cathepsin G is a strong platelet agonist released by neutrophils. Biochem J. 1988; 251: 293-299. (Pubitemid 18099385)
70. D'Anastasio C, Impallomeni M, McPherson GA, et al. Antibodies against monocytes and endothelial cells in the sera of patients with atherosclerotic peripheral arterial disease. Atherosclerosis. 1988; 74: 99-105. (Pubitemid 18266550)
71. Nityanand S, Bergmark C, de Faire U, et al. Antibodies against endothelial cells and cardiolipin in young patients with peripheral atherosclerotic disease. J Int Med. 1995; 238: 437-443.
72. Fischer K, Brzosko M, Walecka A, et al. [Antiendothelial cell antibodies as a risk factor of atherosclerosis in systemic lupus erythematosus]. Ann Acad Med Stetin. 2006; 52 Suppl 2: 95-99. Polish.
73. 2-GPI) in systemic lupus erythematosus. Clin Exp Immunol. 1999; 115: 561-566. (Pubitemid 29130376)
74. Manzi S, Selzer F, Sutton-Tyrrell K, et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum. 1999; 42: 51-59.
75. McDonald J, Stewart J, Urowitz MB, et al. Peripheral vascular disease in patients with systemic lupus erythematosus. Ann Rheum Dis. 1992; 51: 56-60.
76. Petri M, Lakatta C, Magder L, et al. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med. 1994; 96: 254-259. (Pubitemid 24099225)
77. Rahman P, Gladman DG, Urowitz MB, et al. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol. 1999; 26: 325-330. (Pubitemid 29066736)
78. Molad Y, Gorshtein A, Wysenbeek AJ, et al. Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. Lupus. 2002; 11: 356-361.